Triple negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which only chemotherapy and radiation therapy are currently available. The retinoblastoma (RB1) tumor suppressor is frequently lost in human TNBC. Knockdown of RB1 in luminal BC cells was shown to affect response to endocrine, radiation and several antineoplastic drugs. However, the effect of RB1 status on radiation and chemo-sensitivity in TNBC cells and whether RB1 status affects response to divergent or specific treatment are unknown. Using multiple basal-like and claudin-low cell lines, we hereby demonstrate that RB-negative TNBC cell lines are highly sensitive to gamma-irradiation, and moderately more sensitive to doxorubicin and methotrexate compared to RB-positive TNBC cell lines. In contrast, RB1 status did not affect sensitivity of TNBC cells to multiple other drugs including cisplatin (CDDP), 5-fluorouracil, idarubicin, epirubicin, PRIMA-1met, fludarabine and PD-0332991, some of which are used to treat TNBC patients. Moreover, a non-biased screen of ~3400 compounds, including FDA-approved drugs, revealed similar sensitivity of RB-proficient and -deficient TNBC cells. Finally, ESA+/CD24？/low/CD44+ cancer stem cells from RB-negative TNBC lines were consistently more sensitive to gamma-irradiation than RB-positive lines, whereas the effect of chemotherapy on the cancer stem cell fraction varied irrespective of RB1 expression. Our results suggest that patients carrying RB-deficient TNBCs would benefit from gamma-irradiation as well as doxorubicin and methotrexate therapy, but not necessarily from many other anti-neoplastic drugs.
References
[1]
Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5–23.
[2]
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116–4124.
[3]
Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16 Suppl 161–70.
[4]
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13: 4429–4434.
[5]
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, et al. (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28: 375–379.
[6]
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, et al. (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423–428.
[7]
Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677.
[8]
Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671–682.
[9]
Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, et al. (2007) Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res 67: 6192–6203.
[10]
Herschkowitz JI, He X, Fan C, Perou CM (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10: R75.
[11]
Bookstein R, Lee EY, Peccei A, Lee WH (1989) Human retinoblastoma gene: Long-range mapping and analysis of its deletion in a breast cancer cell line. Mol Cell Biol 9: 1628–1634.
[12]
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515–527.
[13]
Lee EY, To H, Shew JY, Bookstein R, Scully P, et al. (1988) Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218–221.
[14]
T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK (1988) Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263–266.
[15]
Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, et al. (1992) Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 23: 1388–1394.
[16]
Varley JM, Brammar WJ, Walker RA (1989) Oncogene organisation and expression: Prediction in breast cancer. Horm Res 32 Suppl 1250–253.
[17]
Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, et al. (1989) The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 4: 725–729.
[18]
Wang NP, To H, Lee WH, Lee EY (1993) Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 8: 279–288.
[19]
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, et al. (2011) RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 10: 1563–1570.
[20]
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
[21]
Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, et al. (2010) Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 120: 3296–3309.
[22]
Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649–4664.
[23]
Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, et al. (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121: 53–64.
[24]
Allis S, Reali A, Mortellaro G, Arcadipane F, Bartoncini S, et al. (2012) Should radiotherapy after primary systemic therapy be administered with the same recommendations made for operable breast cancer patients who receive surgery as first treatment? A critical review. Tumori 98: 543–549.
[25]
Bollet MA, Belin L, Reyal F, Campana F, Dendale R, et al. (2012) Preoperative radio-chemotherapy in early breast cancer patients: Long-term results of a phase II trial. Radiother Oncol 102: 82–88.
[26]
Clark RM, Whelan T, Levine M, Roberts R, Willan A, et al. (1996) Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update. ontario clinical oncology group. J Natl Cancer Inst 88: 1659–1664.
[27]
Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, et al. (1999) 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomized trial. J Clin Oncol 17: 2326–2333.
[28]
Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, et al. (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18: 568–576.
[29]
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, et al. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427–1438.
[30]
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, et al. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11: R77.
[31]
Arslan C, Dizdar O, Altundag K (2009) Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 10: 2081–2093.
[32]
Robinson TJW, Pai M, Liu JC, Vizeacoumar F, Sun T, et al. (2013) High-throughtput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: Interaction with IQ motif-containing factors. Cell Cycle In Press.
[33]
Hassett-Sipple B, Swartout J, Schoeny R (1997) Mercury study report to congress, volume V health effects of mercury and mercury compounds. . Environmental Protection Agency, EPA EPA-452/R-92-007.
[34]
Moeller TA, Shukla SJ, Xia M (2012) Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format. Assay Drug Dev Technol 10: 78–87.
[35]
Fleskens AJ, Lalisang RI, Bos GM, van Gelder M, Jansen RL, et al. (2010) HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Bone Marrow Transplant 45: 464–467.
[36]
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, et al. (2013) Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer.
[37]
McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, et al. (2012) Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. Int J Hematol 96: 743–747.
[38]
Mittelman A, Ashikari R, Ahmed T, Savona S, Arnold P, et al. (1988) Phase II trial of fludarabine phosphate (F-ara-AMP) in patients with advanced breast cancer. Cancer Chemother Pharmacol 22: 63–64.
[39]
Lopez M, Di Lauro L, Papaldo P, Lazzaro B, Ganzina F, et al. (1986) Phase II trial with oral idarubicin in advanced breast cancer. Invest New Drugs 4: 39–42.
[40]
Martoni A, Piana E, Guaraldi M, Cilenti G, Farris A, et al. (1990) Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 47: 427–432.
[41]
Bastholt L, Dalmark M (1987) Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep 71: 451–454.
[42]
Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, et al. (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15: 376–388.
[43]
Dick JE (2003) Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 100: 3547–3549.
[44]
Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21: 283–296.
[45]
Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(？/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777–1785.
[46]
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
[47]
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672–679.
[48]
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106: 13820–13825.
[49]
Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
[50]
Trere D, Brighenti E, Donati G, Ceccarelli C, Santini D, et al. (2009) High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol 20: 1818–1823.
[51]
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, et al. (2007) The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 117: 218–228.
[52]
Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399.
[53]
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
[54]
Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, et al. (2009) Most basal-like breast carcinomas demonstrate the same rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 33: 163–175.
[55]
Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, et al. (2008) Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 14: 2199–2209.
[56]
Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, et al. (2010) RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9: 4153–4163.
[57]
Trere D, Brighenti E, Donati G, Ceccarelli C, Santini D, et al. (2009) High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol 20: 1818–1823.
[58]
Abbas H, Elyamany A, Salem M, Salem A, Binziad S, et al. (2011) The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med 4: 35–7682–4–35.
[59]
Jobsen JJ, van der Palen J, Brinkhuis M, Ong F, Struikmans H (2012) Sequence of radiotherapy and chemotherapy in breast cancer after breast-conserving surgery. Int J Radiat Oncol Biol Phys 82: e811–7.
[60]
Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T (2003) Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223–228.
[61]
Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, et al. (2012) RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 18: 5110–5122.
[62]
Hong JY, Kwon SS, Kim GH, Kim JW, Sato E, et al. (2012) Computational modeling of apoptotic signaling pathways induced by cisplatin. BMC Syst Biol 6: 122.
[63]
Chu FC, Lin FJ, Kim JH, Huh SH, Garmatis CJ (1976) Locally recurrent carcinoma of the breast. results of radiation therapy. Cancer 37: 2677–2681.
[64]
Pierquin B, Baillet F, Wilson JF (1976) Radiation therapy in the management of primary breast cancer. AJR Am J Roentgenol 127: 645–648.
[65]
Veronesi U, Orecchia R, Luini A, Galimberti V, Gatti G, et al. (2005) Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: Experience with 590 cases. Ann Surg 242: 101–106.
[66]
Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, et al. (2010) Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2: 371–384.
[67]
Shahinas D, Liang M, Datti A, Pillai DR (2010) A repurposing strategy identifies novel synergistic inhibitors of plasmodium falciparum heat shock protein 90. J Med Chem 53: 3552–3557.
[68]
Brideau C, Gunter B, Pikounis B, Liaw A (2003) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8: 634–647.
